Adaptive Biotechnologies signed two non‑exclusive agreements with Pfizer to license its T‑cell receptor discovery platform and TCR‑antigen mapping data. Under the first deal Adaptive will apply its immune medicine platform to Pfizer’s clinical samples to identify disease‑associated TCRs for rheumatoid arthritis targets; the second grants Pfizer multi‑year data access to train AI/ML models. Adaptive disclosed potential milestones that could total roughly $890 million under the arrangements. The transactions give Pfizer rights to proprietary immune receptor datasets and analytic tools that can accelerate target discovery and biomarker development in several disease areas. Adaptive will receive upfront payments and could earn additional development and commercial milestones. TCR discovery platforms map T‑cell receptors to antigens and are valuable for both cell therapy and antigen‑targeted drug programs; licensing such data accelerates vaccine, TCR‑T or TCR‑targeted antibody discovery pipelines.